
Assessing Adherence to Secondary Prevention Guidelines for Myocardial Infarction for Patients Discharged from an Alberta Hospital
Cardiology (Heart & Vascular)
2022-06-08 – 2026-03-31
Preventing recurrent myocardial infarction (MI) depends on strong secondary prevention, including appropriate cardiac interventions, medication adherence, and ongoing follow-up care. This project, led by Dr. Robert Welsh and Dr. Pishoy Gouda, examined post-discharge care from the perspective of cardiologists at the Mazankowski Heart Institute. Focusing on 2,464 patients who experienced a MI and received a bare-metal or drug-eluting stent, the study evaluated adherence to guideline-recommended medications and follow-up laboratory testing as care transitioned from hospital to community.
Findings showed strong adherence to recommended cardiac interventions and medications. Among patients treated at the Mazankowski Heart Institute, 91% underwent coronary angiography, 79% received percutaneous coronary intervention (PCI), and 87% received either PCI or coronary artery bypass grafting (CABG). Medication adherence was similarly high, with 93% of patients maintaining antiplatelet therapy in the first three months and 88% between months four and twelve. Long-term use of statins, angiotensin converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs) also remained strong through and beyond the first year.
Supplemental analysis this year by PLP Medical Director Dr. Darren Lau identified an important opportunity for improvement: adults living with diabetes and those with dementia had consistently lower long-term use of these medications, beginning at 4–13 months with further decreases 14-36 months after discharge. While declining kidney function may explain some discontinuation of ACE inhibitor or ARB therapy, reduced long-term statin use in people living with diabetes remains an important care gap, due to their increased risk of cardiovascular events.
Overall, the findings suggest that while broad adherence to secondary prevention is strong, there are opportunities to optimize care for specific patient groups. We are exploring opportunities for dissemination, and considering a possible follow-on study focused on dyslipidemia management to inform QI activities.
This project confirms generally strong adherence to secondary prevention therapies following myocardial infarction in the study population, helping narrow future analytic focus to areas where residual gaps may exist.